Samuel Broder, M.D.

Dr. Samuel Broder has been a scientific advisor for Precision BioSciences since 2018. He has spent a lifetime at the forefront of science and medicine in many diverse arenas. He is the former Director of the National Cancer Institute (NCI). President Ronald Reagan appointed Dr. Broder to serve in this position in 1989, and he continued to serve in this role for six years. He oversaw the development of numerous anti-cancer therapeutic agents. Dr. Broder also helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer, and he inaugurated the highly successful Specialized Program of Research Excellence (SPORE).

He joined the Celera Corporation at its founding in 1998, as the Executive Vice President for Medical Affairs and Chief Medical Officer, and there he helped advance the Human Genome Project. He has served in numerous positions in industry, including membership on a number of Boards and advisory bodies. His most recent senior executive position was as SVP, Health Sector, Intrexon Corp, with responsibilities for gene therapy in various diseases, including recessive dystrophic epidermolysis bullosa, CART, regulated IL-12 gene therapy for glioblastomas, and synthetic biology. He also has an interest in novel neoantigen vaccines and the application of new immunophage platforms as well as therapies that affect the tumor microenvironment to treat advanced cancers.

He graduated from the University of Michigan Medical School in Ann Arbor. Thereafter, he did an internship and residency in Internal Medicine at Stanford University in Palo Alto, and then a subspecialty training in medical oncology at the National Cancer Institute in Bethesda, Maryland. He is the author or co-author of over 340 scientific publications and is an inventor or co-inventor on many patents. He has received numerous awards related to his research in cancer and AIDS. He was elected to the National Academy of Medicine in 1993.